Explore the words cloud of the MEPHOS project. It provides you a very rough idea of what is the project "MEPHOS" about.
The following table provides information about the project.
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
|Coordinator Country||Italy [IT]|
|Total cost||952˙200 €|
|EC max contribution||864˙800 € (91%)|
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
|Duration (year-month-day)||from 2020-04-01 to 2024-03-31|
Take a look of project's partnership.
|1||FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA||IT (GENOVA)||coordinator||312˙800.00|
|2||UNIVERSIDAD DE NAVARRA||ES (PAMPLONA)||participant||253˙000.00|
|3||UNIVERSIDADE DO MINHO||PT (BRAGA)||participant||225˙400.00|
|4||LIPOCURE LTD||IL (JERUSALEM)||participant||73˙600.00|
|5||BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY||US (STANFORD)||partner||0.00|
|6||THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL||US (CHAPEL HILL)||partner||0.00|
|7||University of Arkansas||US (Fayetteville)||partner||0.00|
|8||VANDERBILT UNIVERSITY||US (NASHVILLE TENESSEE)||partner||0.00|
Osteoarthritis (OA) is a chronic disease involving the degeneration of articular cartilage and subchondral bone. It represents the single most common cause of disability in older adults. Being aging, obesity, trauma and gender risk factors for OA, its societal burden is rapidly rising. Across EU, over 40 million people are affected by OA. Current treatment options aim at modulating the symptoms rather than curing this chronic disease. Consequently, joint replacement continues to be ultimately the sole option. In this context, MEPHOS aims at realizing an integrated strategy for OA treatment based on the intra-articular deposition of hydrogel, polymeric microplates (uPLs) that could simultaneously provide a long-term pharmacological action and mechanical support. To this end, the uPL geometry and mechanical properties will be rationally selected to match the viscoelastic behaviour of cartilage and synovial fluid. Over the course of several weeks, uPLs will sustainably release clinically-approved molecules for pain management and novel small molecules and biologicals; including chemokine and metalloproteinase inhibitors to halt tissue degeneration; glycoproteins, growth factors and stem cell-derived extracellular vesicles to favour tissue regeneration. MEPHOS involves three EU Academic Institutions and a SME for uPL fabrication, and four US Academic Institutions for uPL biological and preclinical characterization. Through interdisciplinary and intersectoral secondments, this project will support the training of EU scientists on sophisticated in-vitro assays and three different preclinical OA models; foster the rational development of uPLs; and instil a translational research culture to bridge preclinical-clinical boundaries. The inclusion of a SME and the Stanford SPARK Translation program documents MEPHOS ambition to develop technologies that could hit the clinic and an industrial market, which is predicted to growth from $1.6 billion in 2016 to $3.5 billion by 2026.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEPHOS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MEPHOS" are provided by the European Opendata Portal: CORDIS opendata.